Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Common Equity (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Common Equity for 6 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 53.66% to $26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.5 million through Dec 2025, down 53.66% year-over-year, with the annual reading at $26.5 million for FY2025, 53.66% down from the prior year.
  • Common Equity hit $26.5 million in Q4 2025 for Bolt Biotherapeutics, down from $32.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $303.2 million in Q1 2021 to a low of $26.5 million in Q4 2025.
  • Historically, Common Equity has averaged $146.2 million across 5 years, with a median of $135.2 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 659.24% in 2021 and later crashed 55.43% in 2025.
  • Year by year, Common Equity stood at $250.1 million in 2021, then plummeted by 31.43% to $171.5 million in 2022, then tumbled by 34.26% to $112.7 million in 2023, then plummeted by 49.27% to $57.2 million in 2024, then tumbled by 53.66% to $26.5 million in 2025.
  • Business Quant data shows Common Equity for BOLT at $26.5 million in Q4 2025, $32.1 million in Q3 2025, and $38.8 million in Q2 2025.